RxDoctor Payments Data

Shannon Chang, MD

Gastroenterology · New York, NYNPI 1932423910

Payments from drug & device makers

$81,532in general payments, 2019–2025

Across 208 payments — averaging $391.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$49K
  • Lilly USA, LLC$10K
  • Johnson & Johnson$7K
  • AbbVie$5K
  • E.r. Squibb & Sons, L.L.C.$5K
  • Shire North American Group Inc$4K
  • plus $1K from 12 others
$7,010in research payments, 2019–2025

Across 7 payments — averaging $1001.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$7K

What the payments were for

  • Consulting fees$35,74544%
  • Speaking & faculty fees$21,05626%
  • Travel & lodging$19,30624%
  • Food & beverage$4,0935%
  • Education$1,3322%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,532 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$34,725
Medicare patients
105
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab103$2,848,960
Skyrizi On-BodyRisankizumab-Rzaa17$331,472
Humira(Cf) PenAdalimumab13$184,813
ZeposiaOzanimod Hydrochloride12$108,808
Entyvio PenVedolizumab13$75,926
XifaxanRifaximin13$52,378
Mesalamine52$28,803
Mesalamine ErMesalamine35$14,712
Budesonide ErBudesonide11$10,094
Tenofovir Disoproxil Fumarate13$2,010
LoperamideLoperamide Hcl30$1,552
Colestipol Hcl30$1,180
CholestyramineCholestyramine (With Sugar)13$1,132
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine15$960
MethotrexateMethotrexate Sodium16$737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$7,326$2,848,960103 claims
E.r. Squibb & Sons, L.L.C.Zeposia$4,680$108,80812 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$60$52,37813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →